The FDANews is reporting that
the European Medicine Agency’s
(EMEA) Paediatric Committee has
decided not to recommend use of
Vytorin®. . . for treating high cholesterol
in children. Quoth FDANews:
The cholesterol drugs “do not
represent a significant therapeutic
benefit over existing treatments,” the
EMEA says in a statement. . . .. . . .The drugmaker markets Vytorin
through a joint venture with Schering-Plough. . . .Recently, two congressmen asked the
FDA to release a new study they say
links Vytorin to cancer. . . .
Ouch. Common sense makes a comeback, yes?
